Pure Global
NCT06385223

A Novel Individualized Connectome-guided Approach for Precision Intermittent Theta Burst Stimulation for Depression

A Novel Individualized Connectome-guided Approach for Precision Intermittent Theta Burst Stimulation for Depression: a Double Blind, Randomized Controlled Trial
Institute of Mental Health, Singapore·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Depression
Drug/Device/Intervention
Beam F3 targeted accelerated iTBS
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Institute of Mental Health, Singapore
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2024
End date
Dec 31, 2026
Enrollment
70 participants
Primary outcome

Montgomery-Åsberg Depression Rating Scale

Summary

The Investigators propose to carry out a randomized, double-blind trial to compare the
 clinical efficacy of an individualized connectome-guided accelerated iTBS vs an
 anatomically-guided (Beam F3) accelerated iTBS. The study team will recruit both inpatients
 and outpatients who had been referred for TMS for the treatment of depression.

ICD-10 classifications
Depressive episodeOther depressive episodesRecurrent depressive disorderRecurrent depressive disorder, unspecifiedPost-schizophrenic depression
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06385223
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06385223 through Pure Global AI's free database. This phase not specified trial is sponsored by Institute of Mental Health, Singapore and is currently Not yet recruiting. The study focuses on Depression. Target enrollment is 70 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.